Recent Pfizer Press Releases

  • 10/20/18 10:30 am EDT

    Results Presented at the ESMO 2018 Congress (European Society for Medical Oncology) and Simultaneously Published in The New England Journal of Medicine

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc.(NYSE:PFE) today announced detailed overall survival (OS) data from the PALOMA-3 trial, which evaluated IBRANCE® (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy. In the study, there was a numerical improvement inmore...
  • 10/9/18 9:05 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced its executive team that will report to Albert Bourla, incoming Chief Executive Officer, coincident with the commencement of his new role effective January 1, 2019. “We are at a pivotal moment in Pfizer’s history, with Ian Read having positioned the company with a strong portfolio of marketed products, a deep pipeline and the clear potential to accelerate our revenue growth,”more...
  • 10/1/18 6:45 am EDT
    • Effective January 1, 2019, Dr. Albert Bourla to become Chief Executive Officer (CEO) and Ian Read to serve as Executive Chairman of the Board of Directors
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced its Board of Directors has unanimously elected Dr. Albert Bourla, 56, Pfizer Chief Operating Officer (COO), to succeed Ian Read as CEO effective January 1, 2019. Ian Read will transition from his current role as Chairman and CEO to Executive Chairman of Pfizer’s Board of Directors. “It’s been an honor to serve as Pfizer’s CEO for the past eight years,” stated Ian Read. “Howevermore...
  • 9/27/18 5:41 pm EDT

    Approval Supported by Data from Phase 3 Head-to-Head Study vs. Gefitinib

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved VIZIMPRO® [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. “Improving outcomes formore...
  • 9/27/18 1:09 pm EDT
    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 34-cent fourth-quarter 2018 dividend on the company’s common stock, payable December 3, 2018, to shareholders of record at the close of business on November 9, 2018. The third-quarter 2018 cash dividend will be the 320th consecutive quarterly dividend paid by Pfizer. Working together for a healthier world® At Pfizer, we apply science and our globalmore...
  • 9/20/18 8:00 am EDT

    Breakthrough Therapy Designation Designed by FDA to Expedite the Development and Review of Drugs and Vaccines Which May Demonstrate Substantial Improvement Over Available Therapy 1

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older.2 Pfizer expects to start Phase 3 trials in a few months. Themore...
  • 9/18/18 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 30, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit ourmore...
  • 9/18/18 9:00 am EDT

    —Findings from sensitivity and post-hoc analyses were presented during a Late Breaking Clinical Trials Session at the Heart Failure Society of America 22 nd Annual Scientific Meeting—

    —Results of new analyses of all-cause mortality favored tafamidis across all sub-groups—

    —29% and 31% reduction in the risk of death observed in wild-type and hereditary sub-groups, respectively—

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that additional sensitivity and post-hoc analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) study provide further detail on the effect of tafamidis across wild-type, hereditary, and New York Heart Association (NYHA) class sub-groups of patients with transthyretin amyloid cardiomyopathy (ATTR-CM).1 Tafamidis is the only investigational treatment that hasmore...
  • 9/15/18 2:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, compared to placebo, in patients with moderate to severe alopecia areata (AA), an autoimmune disease characterized by hair loss and often associated with profound psychological consequences. Both JAK inhibitors met the primary efficacymore...
  • 9/6/18 11:30 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Executive Vice President, Business Operations, and Chief Financial Officer, at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 at 2:55 p.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessingmore...